Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 10월 2021 - 9:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
two poster presentations at the SITC 2021 Annual Meeting, which is
being held November 10-14, 2021 in Washington, D.C.
Details are as follows:
Title: First-in-Human Results with the Novel
Tumor-Targeting Antibody ATRC-101: Phase 1b Study in Patients with
Solid TumorsPoster/Abstract Number:
518Date/Time: November 12 - November 13, 7:00 a.m.
- 8:30 p.m. ET
Title: Preclinical Evaluation of Pegylated
Liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6
Syngeneic Mouse ModelPoster/Abstract Number:
559Date/Time: November 12 - November 14, 7:00 a.m.
- 8:30 p.m. ET
Full text of the abstracts will be released on the SITC website
at 8:00 a.m. ET on Tuesday, November 9, 2021, and the posters will
be made available on the company’s website at 7:00 a.m. ET on
November 12, 2021.
About Atreca, Inc.Atreca is a biopharmaceutical
company developing novel antibody-based immunotherapeutics
generated by its differentiated discovery platform. Atreca’s
platform allows access to an unexplored landscape in oncology
through the identification of unique antibody-target pairs
generated by the human immune system during an active immune
response against tumors. These antibodies provide the basis for
first-in-class therapeutic candidates, such as our lead product
candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in
multiple solid tumor cancers is currently enrolling patients. For
more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and typically are identified by use of terms such as
"continued," "anticipate," "potential," "expect," "believe,"
"planned," and similar words, although some forward-looking
statements are expressed differently. These statements include
those related to our strategy and future plans, including
statements regarding the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, clinical
trials, regulatory submissions, and other matters that are
described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, 650-779-9251, ext. 251agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024